home / stock / phrm:cc / phrm:cc news

PHRM:CC News and Press, Pharmather Holdings Ltd. From 08/08/25

Stock Information
Company Name: Pharmather Holdings Ltd.
Stock Symbol: PHRM:CC
Market: CNQC
Website: pharmather.com
Menu
PHRM:CC PHRM:CC Quote PHRM:CC Short PHRM:CC News PHRM:CC Articles PHRM:CC Message Board
Get PHRM:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
PHRM:CC - Canadian Investment Regulatory Organization Trading Halt - PHRM

Canadian Investment Regulatory Organization Trading Halt - PHRM Canada NewsWire VANCOUVER, BC , Aug. 8, 2025 /CNW/ - The following issues have been halted by CIRO: Company: PharmaTher Holdings Ltd. CSE Symbol: PHRM All Issues: Yes Reason: ...
PHRM:CC - PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine

TORONTO, July 02, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the development and commercialization of ketamine-based pharmaceuticals, is pleased to provide ...

PHRM:CC - PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U....

PHRM:CC - PharmaTher Applauds FDA's New Commissioner's National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications

TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, today announced its strong support for the U.S. Food and Drug Administration's (FDA) new Commiss...
PHRM:CC - PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025

TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a specialty pharmaceutical company focused on ketamine for unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) has extended the approval goal...

PHRM:CC - PharmaTher Unveils KetaVault(TM): A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization

TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the research and commercialization of ketamine for unmet medical needs, today announced the laun...

PHRM:CC - PharmaTher Receives US FDA Approval Goal Date for Ketamine

TORONTO, March 11, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company hyper-focused on the commercialization of Ketamine, is pleased to announce today that the Company has rec...
PHRM:CC - PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine

Expecting FDA approval of Ketamine in Q2-2025 Solving the shortage problem of Ketamine and unlocking its pharmaceutical potential Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutic...

PHRM:CC - PharmaTher Provides Update on FDA New Drug Application for Ketamine

TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company seeking FDA approval for ketamine, today announced that the Company is on track to resubmit information to...

PHRM:CC - PharmaTher CEO Issues Letter to Shareholders

TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on the development and commercialization of ketamine, announced today that Fabio Chianelli, the Co...
Previous 10 Next 10